Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vaxcyte ( (PCVX) ) is now available.
On January 29, 2026, Vaxcyte, Inc. entered into an underwriting agreement with a syndicate of investment banks to conduct a public offering of 11,000,000 shares of its common stock at $50.00 per share, with the underwriters purchasing the shares at $47.50 per share. The company granted the underwriters a 30-day option to buy up to an additional 1,650,000 shares, which the underwriters elected to exercise in full on January 30, 2026, bringing total net proceeds to approximately $600.2 million after underwriting discounts, commissions and expenses; the offering, made under an effective shelf registration, closed on February 2, 2026 and strengthens Vaxcyte’s capital position, potentially enhancing its ability to fund development programs and reinforcing its standing in the competitive vaccine development sector.
The most recent analyst rating on (PCVX) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Vaxcyte stock, see the PCVX Stock Forecast page.
Spark’s Take on PCVX Stock
According to Spark, TipRanks’ AI Analyst, PCVX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technicals are moderately constructive with price above key moving averages and neutral momentum, while valuation is constrained by ongoing losses. Corporate events add a small positive tilt through manufacturing readiness, tempered by higher executive severance obligations.
To see Spark’s full report on PCVX stock, click here.
More about Vaxcyte
Vaxcyte, Inc. is a biopharmaceutical company operating in the vaccine industry, focused on developing next-generation vaccines based on advanced conjugation and protein engineering technologies to address serious infectious diseases in global markets.
Average Trading Volume: 1,390,699
Technical Sentiment Signal: Buy
Current Market Cap: $7.01B
Learn more about PCVX stock on TipRanks’ Stock Analysis page.